FdaApplication
BLA 761171
Identifiers
- fda_app_no: BLA761171
Properties
| Property | Value |
|---|---|
| applicant_name | Y-mABs Therapeutics, Inc |
| application_type | BLA |
| approval_date | 2020-11-25 |
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| DANYELZA | NAXITAMAB-GQGK | 40MG/10ML (4MG/ML) | Injection |
1 product